| Support Through Remote Observation and Nutrition Guidance (STRONG) Program for Gastroesophageal Cancer (GEC) Patients (NCT05438940) | H. Lee Moffitt Cancer Center and Research Institute | 2022-07-15 |
| FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors (NCT05395052) | Fate Therapeutics | 2022-05-31 |
| Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers (NCT05205343) | M.D. Anderson Cancer Center | 2022-05-11 |
| A Systems Approach to Immunotherapy Biomarker Identification Within the Postoperative Wound-Healing Microenvironment in Patients With Gastroesophageal Cancer (NCT05338060) | Inova Health Care Services | 2022-01-26 |
| Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma (NCT05122091) | Guangxi Medical University | 2021-11-05 |
| ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117) | QuantumLeap Healthcare Collaborative | 2021-07-28 |
| Imaging and Blood-Based Biomarkers for the Evaluation of Early Signs of Myocardial Injury After Thoracic Radiation Therapy (NCT05717998) | Ohio State University Comprehensive Cancer Center | 2021-04-02 |
| Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma (NCT04069273) | Harry H Yoon | 2020-12-01 |
| Supportive Oncology Care At Home RCT (NCT04544046) | Massachusetts General Hospital | 2020-09-16 |
| Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy (NCT04555304) | Chengdu Kanghong Biotech Co., Ltd. | 2020-09-15 |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (NCT04504669) | AstraZeneca | 2020-08-18 |
| A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection (NCT04510285) | Memorial Sloan Kettering Cancer Center | 2020-08-10 |
| A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer (NCT04363801) | Leap Therapeutics, Inc. | 2020-07-29 |
| Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer (NCT04294784) | Huazhong University of Science and Technology | 2020-04-03 |
| Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma (NCT04281576) | NovoCure Ltd. | 2019-12-19 |
| Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (NCT03818997) | European Organisation for Research and Treatment of Cancer - EORTC | 2019-12-01 |
| Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (NCT03983954) | NeoTX Therapeutics Ltd. | 2019-10-10 |
| Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer (NCT04385641) | Shandong Golden Brick Biotechnology Co., Ltd. | 2019-10-08 |
| An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients (NCT04099641) | OncXerna Theraputics, Inc. | 2019-09-11 |
| Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 (NCT03997448) | Nataliya Uboha | 2019-08-26 |
| TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (NCT04074343) | University of California, Irvine | 2019-08-26 |
| Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (NCT03798626) | Novartis Pharmaceuticals | 2019-05-22 |
| TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (NCT03829436) | Tempest Therapeutics | 2019-03-20 |
| A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy (NCT03813784) | Jiangsu HengRui Medicine Co., Ltd. | 2019-03-07 |
| REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer (NCT03610711) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2019-03-06 |
| Comparison Between Double Tract Anastomosis and Esophagogastrostomy After Radical Proximal Gastrectomy (NCT03613142) | Peking University Cancer Hospital & Institute | 2019-01-01 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (NCT03775850) | Evelo Biosciences, Inc. | 2018-12-19 |
| A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies (NCT03720678) | Arcus Biosciences, Inc. | 2018-11-18 |
| PREoperativ Study of Exercise Training (NCT03490565) | Jesper Frank Christensen, PhD | 2018-08-16 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer (NCT03490292) | University of Wisconsin, Madison | 2018-05-29 |
| A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer (NCT03472365) | Jiangsu HengRui Medicine Co., Ltd. | 2018-04-02 |
| Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (NCT03409848) | AIO-Studien-gGmbH | 2018-03-01 |
| A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (NCT03416244) | AIO-Studien-gGmbH | 2018-02-21 |
| A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers (NCT03279237) | Massachusetts General Hospital | 2017-10-24 |
| A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies (NCT03321630) | NYU Langone Health | 2017-10-24 |
| APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers (NCT03165994) | Apexigen America, Inc. | 2017-10-06 |
| Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (NCT03044613) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-07-11 |
| Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression (NCT03125200) | ADC Therapeutics S.A. | 2017-05-18 |
| Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy (NCT02853474) | Centre Oscar Lambret | 2016-10-01 |
| MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors (NCT02669914) | Washington University School of Medicine | 2016-09-12 |
| A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours (NCT02586987) | AstraZeneca | 2015-12-28 |
| Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer (NCT02317991) | SCRI Development Innovations, LLC | 2015-05-05 |
| A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab (NCT02013154) | Leap Therapeutics, Inc. | 2014-05-05 |
| Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. (NCT01715233) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2012-12-01 |
| Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach (NCT01611857) | SCRI Development Innovations, LLC | 2012-07-01 |
| Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer (NCT01145404) | National Center for Tumor Diseases, Heidelberg | 2010-06-01 |
| Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT (NCT00718354) | Thrombosis Research Institute | 2008-07-01 |
| FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer (NCT00673673) | Yale University | 2008-05-01 |
| Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma (NCT00256269) | University of California, Irvine | 2005-06-01 |
| Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma (NCT00525915) | M.D. Anderson Cancer Center | 2005-04-01 |
| Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction (NCT00080002) | Enzon Pharmaceuticals, Inc. | 2003-12-01 |
| Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors (NCT04681248) | Leap Therapeutics, Inc. | |